Prelude Therapeutics (PRLD) PT Raised to $6 at Citizens on Favourable Clinical Data
Tweet Send to a Friend
Citizens analyst Reni Benjamin raised the price target on Prelude Therapeutics (NASDAQ: PRLD) to $6.00 (from $3.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
